Mary Crowley Cancer Research Centers and Introgen Therapeutics, Inc. Release: Groundbreaking Clinical Trial at Mary Crowley Significantly Increases Survival in End-Stage Head and Neck Cancer Patients

DALLAS, TX--(Marketwire - May 29, 2008) - Mary Crowley Cancer Research Centers (Mary Crowley) in partnership with Introgen Therapeutics, Inc. (Introgen) announced that ADVEXIN® significantly increased survival in end-stage head and neck cancer patients. The phase 3 clinical trial was led by principal investigator John Nemunaitis, M.D., Executive Medical Director of the Mary Crowley Cancer Research Centers, located at the Baylor University Medical Center in Dallas.